Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting,...
Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2 Statistically significant improvements ...
Independent European source of exatecan will expand choice and strengthen supply resilience for ADC developers Gram-scale material available, with...
Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2...
Beactica Therapeutics AB, a Swedish precision medicine company, announced the selection of BEA-28 as a preclinical candidate for its TEAD programme, which ...
Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background Administered...
AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBM...
Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, announced positive results from a prospective, multicenter randomized controlled tr...
Treatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duratio...
SkinHealth Systems (Nasdaq: SKIN), home to flagship brand Hydrafacial™, announced the European expansion of the SkinStylus® SteriLock® MicroS...
Phase 1 study is evaluating the safety, tolerability and pharmacokinetics of Mironid’s lead LoAc® small molecule in healthy volunteers Dosing ...
Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in dela...
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in a...
EGL-003, a selective IL-2 agonist, was well tolerated across all four dose cohorts. EGL-003 produced selective, dose-dependent Treg expansion without am...
© 2026 Biopharma Boardroom. All Rights Reserved.
